~~UNITED~~U.S. ~~STATES~~ SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~report~~Report (date of earliest event reported): July ~~April 30~~10, 2013

~~MEDISAFE~~Medisafe 1 ~~TECHNOLOGIES~~Technologies ~~CORP~~Corp.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in its ~~Charter~~charter)

~~Commission File No.: 333-161914~~Delaware

Delaware	46-0523031
(State of Incorporation)	(I.R.S. Employer Identification No.)
5a Hataltan Street, Jerusalem, Israel	96926
(Address of Principal Executive Offices)	(ZIP Code)

(State or other jurisdiction of incorporation)

Registrant's Telephone Number, including area code: + 972-77-3318877

333-161914	46-0523031
(Commission File No.)	(IRS Employer Identification No.)

~~Check~~c/o ~~the~~Jacob ~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):~~Elhadad

5A Hataltan Street

Jerusalem , Israel 96926

Phone Number 972-77-3318877

Fax number 972-77-3318879

(Address and telephone number of principal executive offices and place of business)

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.~~14a~~14-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule ~~13e~~13ed-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~Section ~~8.01~~5 ~~Other~~-- ~~Events~~Corporate Governance and Management

OnItem ~~January 15, 2013, Medisafe 1 Technologies corp~~5.03 ~~(the~~Amendments ~~“Company”) issued a release announcing its intention~~ to ~~pay~~Articles ~~a special stock dividend to its shareholders consisting~~ of 10Incorporation ~~million~~or ~~shares of Safecode Drug Technologies Corp. (OTCQB: “SAFC”) that the Company received in connection with a License Agreement dated November 15~~Bylaws, ~~2012.~~Change ~~The execution of the License Agreement was reported~~ in ~~the~~Fiscal ~~Company's Current Report on Form 8-K filed with the SEC on November 20, 2012~~Year. The January 15 Release contemplated that the stock dividend would be paid during the second quarter of 2013. The Company subsequently determined that the date of the special stock dividend distribution would be May 6, 2013.

~~The~~On ~~Company~~or isabout ~~reporting~~September in30, ~~this~~2011, ~~Form~~the Company ~~8-K~~received ~~the~~written ~~delay~~consents in ~~the~~lieu ~~payment~~of ~~date~~a meeting of ~~the~~stockholders ~~stock~~from ~~dividend,~~holders ~~which~~of isa ~~subject~~majority toof the ~~approval~~shares of ~~FINRA~~Common Stock representing in excess of 50.1 % of the ~~corporate~~total ~~action. The~~issued ~~Company~~and ~~has~~outstanding ~~engaged~~shares of voting stock of the Company approving a ~~professional~~Certificate ~~firm~~of Amendment to ~~proceed~~the ~~with~~Certificate of Incorporation of the ~~FINRA~~Company, ~~application~~pursuant ~~and~~to ~~will~~which ~~announce~~the aCompany ~~projected~~will ~~new~~change ~~payment distribution~~, increase ~~date~~the ~~pending~~authorized capital of the ~~progress~~Company to a total of ~~its~~2,000,000,000 ~~application~~shares of common stock with ~~FINRA~~a par value of $0.0001 per share.

~~Item~~The 9Company however only or about February 1 2013 , 2012, filed with the Secretary of the State of Delaware to amend the authorized capital of the Corporation to be 2,000,000,000 shares of common stock, par value of $0.010001. The ~~Financial~~filing ~~Statements~~was initiated at this time, due to the necessity of the agreements with Asher Enterprises and ~~Exhibits~~the associated convertible loans and convertible loan document requirements.

(b) The following documents are filed by the Registrant as exhibits to this current report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.SIGNATURES

~~Exhibit~~Pursuant ~~No.~~to ~~Description~~the requirements of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~99.1~~Dated: ~~License~~July ~~Agreement between the Registrant and Safecode Drug Technologies Corp. dated November 15~~10, ~~2012, filed herewith.~~2013

SIGNATURES

	Medisafe 1 Technologies Corp.

	By:	Jacob Elhadad
		Jacob Elhadad
		Title: President and Director (Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Medisafe 1 Technologies Corp.
	By:	/s/ Jacob Elhadad
	Name: Jacob Elhadad
	Title: President
	Date: April 30 2013

Filing Compare · MEDISAFE 1 TECHNOLOGIES CORP